Reduced pelvic pain in women with endometriosis: efficacy of long-term dienogest treatment
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index; 3 of the 30 sources its claims cite were checked for support.
Abstract
PURPOSE: To investigate the efficacy and safety of dienogest as a long-term treatment in endometriosis, with follow-up after treatment discontinuation. The study included women with endometriosis, who had previously completed a 12-week, placebo-controlled study of dienogest, who participated in an open-label extension study for up to 53 weeks. Thereafter, a patient subgroup was evaluated in a 24-week follow-up after treatment discontinuation. METHODS: A multicenter study performed in Germany, Italy and Ukraine. Women with endometriosis were enrolled at completion of the placebo-controlled study (n = 168). All women received dienogest (2 mg once daily, orally) and changes in pelvic pain (on a visual analog scale), bleeding pattern, adverse events and laboratory parameters were evaluated during and after treatment. RESULTS: The completion rate among women who entered the open-label extension study was 90.5% (n = 152). A significant decrease in pelvic pain was shown during continued dienogest treatment (P < 0.001). The mean frequency and intensity of bleeding progressively decreased. Adverse events, rated generally mild or moderate, led to withdrawal in four patients (2.4%). No clinically relevant changes in laboratory parameters were observed. During treatment-free follow-up (n = 34), the reduction in pelvic pain persisted, while bleeding frequency and intensity returned to normal patterns. CONCLUSIONS: Long-term dienogest showed a favorable efficacy and safety profile, with progressive decreases in pain and bleeding irregularities during continued treatment; the decrease of pelvic pain persisted for at least 24 weeks after treatment cessation.
Overview
CoChat Summary
TL;DR
In women with endometriosis who completed a prior 12-week placebo-controlled dienogest trial, continued open-label dienogest 2 mg/day for up to 53 weeks significantly reduced endometriosis-associated pelvic pain, with the reduction persisting during 24 weeks of treatment-free follow-up. Long-term dienogest also progressively reduced bleeding frequency/intensity and showed a generally mild-to-moderate adverse-event profile.
Key findings
- Among 168 women entering the extension study, 152 (90.5%) completed planned treatment; mean VAS for pelvic pain decreased from 34.08 ± 21.60 mm at extension baseline to 11.52 ± 11.26 mm at end of treatment, with a mean reduction of 43.2 ± 21.7 mm over the total 65-week treatment period (P < 0.001).
- During treatment-free follow-up (n = 34), pain reduction largely persisted: mean VAS was 16.29 ± 14.08 mm at week 12 and 14.56 ± 9.55 mm at week 24.
- Bleeding pattern improved during continued treatment: women with “no bleeding” in 90-day reference periods increased from 5.5% to 23.5%, while “heavy bleeding” decreased from 9.8% to 2.2%; bleeding returned to normal cyclic patterns within 4–6 weeks after treatment cessation.
- Treatment-related adverse events occurred in 27/168 women (16.1%), most commonly breast discomfort (4.2%), nausea (3.0%), and irritability (2.4%); adverse events led to withdrawal in 4 patients (2.4%), and 3 women (1.8%) had serious adverse events.
Methods
- Open-label, single-arm extension study at 28 centers in Germany, Italy, and Ukraine; 168 women with laparoscopically confirmed endometriosis who had completed a 12-week randomized, double-blind, placebo-controlled dienogest study received dienogest 2 mg once daily orally for up to 53 weeks (total treatment up to 65 weeks).
- A subgroup of 34 women at six centers entered a 24-week treatment-free follow-up after the extension study.
- Main assessments included endometriosis-associated pelvic pain by 100-mm VAS every 4 weeks, uterine bleeding pattern over 90-day reference periods, adverse events, laboratory parameters, vital signs, body weight, and SF-36 quality of life; analyses used the full analysis set and were primarily descriptive, with a one-sample t test for change in VAS from randomization to end of extension.
Limitations
- The authors state potential weaknesses: the open-label design and recruitment of patients who had participated in an earlier placebo-controlled study, including a proportion who responded favorably to prior dienogest therapy.
- The extension study was single-arm with no concurrent placebo or active comparator, so long-term efficacy is not compared against another treatment.
- The treatment-free follow-up was limited to a small subgroup (n = 34) at six centers, and efficacy/safety analyses were primarily descriptive; the protocol treatment duration was also changed from 36 to 52 weeks, with 26 patients completing before this prolongation.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
3 Valid · 0 Not valid · 17 Not checked · 37 Own results and interpretations
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“In addition, there were minimal changes in mean body weight, consistent with the previous dienogest experience [13, 14, 16].”
§ Reduced pelvic pain in women with endometriosis: efficacy of long-term dienogest treatment > Discussion
What the sources say
- Not checked yetcites [13] Köhler G, Faustmann TA, Gerlinger C, Seitz C, Mueck AO (2010) A dose-ranging study to determine the efficacy and safety of 1, 2, and 4 mg of dienogest daily for endometriosis. Int J Gynaecol Obstet 108:21–25 source
- Supportedcites [14] Strowitzki T, Marr J, Gerlinger C, Faustmann T, Seitz C (2010) Dienogest is as effective as leuprolide acetate in treating the painful symptoms of endometriosis: a 24-week, randomized, multicentre, open-label trial. Hum Reprod 25:633–641 source
The 'Vital signs and weight' results section states that mean body weight increased only marginally in the dienogest group (1.21 ± 4.12 kg) and to a similar extent with leuprolide acetate, and the Discussion adds that 'weight gain... was minimal in dienogest-treated women'. The same Discussion paragraph ties this to earlier work, stating that the safety and tolerability findings of this trial support the findings of previous studies of dienogest in endometriosis (Köhler 1989/2010, Schindler 2006, Seitz 2008, Harada 2009), which covers the 'consistent with the previous dienogest experience' clause. Note the paper's link to prior dienogest experience is framed for overall safety/tolerability rather than body weight specifically. (LLM, conf=0.85)
- Not checked yetcites [16] Strowitzki T, Faustmann A, Christoph G, Seitz C (2010) Dienogest in the treatment of endometriosis-associated pelvic pain: a 12-week, randomized, double-blind, placebo-controlled study. Eur J Obstet Gynecol Reprod Biol 151:193–198 source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“The lack of changes in laboratory parameters supports previous trials that investigated the metabolic effects of dienogest [13, 14, 16, 23].”
§ Reduced pelvic pain in women with endometriosis: efficacy of long-term dienogest treatment > Discussion
What the sources say
- Not checked yetcites [13] Köhler G, Faustmann TA, Gerlinger C, Seitz C, Mueck AO (2010) A dose-ranging study to determine the efficacy and safety of 1, 2, and 4 mg of dienogest daily for endometriosis. Int J Gynaecol Obstet 108:21–25 source
- Supportedcites [14] Strowitzki T, Marr J, Gerlinger C, Faustmann T, Seitz C (2010) Dienogest is as effective as leuprolide acetate in treating the painful symptoms of endometriosis: a 24-week, randomized, multicentre, open-label trial. Hum Reprod 25:633–641 source
The citation is offered to identify a previous trial of dienogest's metabolic effects, and our copy is exactly that: a 24-week randomized dienogest-vs-leuprolide trial whose 'Clinical laboratory parameters' section states that no changes in standard laboratory parameters between screening and final visit in either group were considered clinically significant, alongside stable estradiol in the dienogest subgroup. Its 'Markers of bone metabolism' and 'Bone mineral density' sections report unchanged lumbar BMD and no increase in bone resorption/formation markers with dienogest, i.e. metabolic assessments. One caveat: the lipid ('no relevant effect on lipids') point in the Discussion is credited by this paper to Kohler 1989/2010, Schindler 2006 and Seitz 2008 rather than being its own measurement, but the claim only requires that this work be a trial investigating dienogest's metabolic effects. (LLM, conf=0.82)
- Not checked yetcites [16] Strowitzki T, Faustmann A, Christoph G, Seitz C (2010) Dienogest in the treatment of endometriosis-associated pelvic pain: a 12-week, randomized, double-blind, placebo-controlled study. Eur J Obstet Gynecol Reprod Biol 151:193–198 source
- Not checked yetcites [23] Schindler AE, Henkel A, Moore C, Oettel M (2009) Effect and safety of high-dose dienogest (20 mg/day) in the treatment of women with endometriosis. Arch Gynecol Obstet 282:507–514 source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The mean VAS score at baseline of the extension study was 34.08 mm (standard deviation [SD] ±21.60 mm) in the total population, resulting from mean scores of 27.89 (±20.24) mm in the dienogest-treated and 40.73 (±21.14) mm in the placebo-treated subgroup.”
§ Reduced pelvic pain in women with endometriosis: efficacy of long-term dienogest treatment > Results > Pelvic pain
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“During treatment-free follow-up, bleeding returned to normal cyclic patterns and intensity within 4–6 weeks.”
§ Reduced pelvic pain in women with endometriosis: efficacy of long-term dienogest treatment > Results > Uterine bleeding pattern
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Adverse events considered potentially drug related by the investigators developed in 27/168 women (16.1%) during the extension study, including breast discomfort (n = 7; 4.2%), nausea (n = 5; 3.0%) and irritability (n = 4; 2.4%).”
§ Reduced pelvic pain in women with endometriosis: efficacy of long-term dienogest treatment > Results > Safety variables
plainn = 168- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
19 more claims
Create a free account to see all 57 claims and to verify the 27 references still open.
- Probably not a substantial claim. 20
- It may state two separate claims as one. 20
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Progestins can be used in women with metabolic or cardiovascular contraindications to estrogen–progestins and limit the risk of post-operative dysmenorrhea recurrence also when released locally via an intrauterine system (Strowitzki et al., 2010; Brown et al., 2012; Petraglia et al., 2012; Abou-Setta et al., 2013).”
From When more is not better: 10 ‘don’ts’ in endometriosis management. An ETIC* position statement (2019) · cites this paper as Petraglia et al., 2012
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Progestins can be used in women with metabolic or cardiovascular contraindications to estrogen–progestins and limit the risk of post-operative dysmenorrhea recurrence also when released locally via an intrauterine system (Strowitzki et al., 2010; Brown et al., 2012; Petraglia et al., 2012; Abou-Setta et al., 2013).”
From When more is not better: 10 ‘don’ts’ in endometriosis management. An ETIC* position statement (2019) · cites this paper as Petraglia et al., 2012
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Reduced pelvic pain in women with endometriosis: efficacy of long-term dienogest treatment > Materials and methods
“Twenty-six patients completed the study before this prolongation was introduced to the protocol.”
§ Reduced pelvic pain in women with endometriosis: efficacy of long-term dienogest treatment > Results
“A total of 152 women (90.5%) completed the planned duration of the extension study (n = 17, 36 weeks; n = 135, 52 weeks).”
Citations
Cites
Revised American Society for Reproductive Medicine classification of endometriosis: 1996
American Society for Reproductive Medicine (1997) · Fertility and Sterility · doi:10.1016/s0015-0282(97)81391-x · Cited by 3,018
Recurrence of endometriosis and its control
Guo, S.-W. (2009) · Human Reproduction Update · doi:10.1093/humupd/dmp007 · Cited by 719
Strowitzki, T., Marr, J., Gerlinger, C., Faustmann, T., & Seitz, C. (2010) · Human Reproduction · doi:10.1093/humrep/dep469 · Cited by 381 · cited 3×
“The lack of changes in laboratory parameters supports previous trials that investigated the metabolic eVects of dienogest [13, 14 , 16, 23].”
ResultInfluentialSelf-citationHarada, T., Momoeda, M., Taketani, Y., Hoshiai, H., & Terakawa, N. (2008) · Fertility and Sterility · doi:10.1016/j.fertnstert.2007.08.051 · Cited by 289
Harada, T., Momoeda, M., Taketani, Y., Aso, T., Fukunaga, M., Hagino, H., & Terakawa, N. (2009) · Fertility and Sterility · doi:10.1016/j.fertnstert.2007.12.080 · Cited by 279
Advances in the management of endometriosis: an update for clinicians
Crosignani, P., Olive, D., Bergqvist, A., & Luciano, A. (2006) · Human Reproduction Update · doi:10.1093/humupd/dmi049 · Cited by 237
Strowitzki, T., Faustmann, T., Gerlinger, C., & Seitz, C. (2010) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2010.04.002 · Cited by 227 · cited 8×
“EAPP score of at least 30 mm on a 100-mm visual analog scale (VAS) at screening and baseline visits [16].”
BackgroundMethodResultSelf-citationLong‐term use of dienogest for the treatment of endometriosis
Momoeda, M., Harada, T., Terakawa, N., Aso, T., Fukunaga, M., Hagino, H., & Taketani, Y. (2009) · Journal of Obstetrics and Gynaecology Research · doi:10.1111/j.1447-0756.2009.01076.x · Cited by 192
Endometriosis: Current Therapies and New Pharmacological Developments
Vercellini, P., Somigliana, E., Viganò, P., Abbiati, A., Barbara, G., & Crosignani, P. G. (2009) · Drugs · doi:10.2165/00003495-200969060-00002 · Cited by 182
Köhler, G., Faustmann, T. A., Gerlinger, C., Seitz, C., & Mueck, A. O. (2010) · International Journal of Gynecology & Obstetrics · doi:10.1016/j.ijgo.2009.08.020 · Cited by 159
Self-citation
Cited by
ESHRE guideline: endometriosis
Becker, C. M., Bokor, A., Heikinheimo, O., Horne, A., Jansen, F., Kiesel, L., King, K., Kvaskoff, M., Nap, A., Petersen, K., et al. (2022) · Human Reproduction Open · doi:10.1093/hropen/hoac009 · Cited by 1,712
“It is recommended to prescribe women progestogens to reduce endometriosis-associated pain (Momoeda et al. , 2009; Brown et al. , 2012; Petraglia et al. , 2012; Andres et al. , 2015; Dragoman and Gaffield, 2016).”
Rethinking mechanisms, diagnosis and management of endometriosis
Chapron, C., Marcellin, L., Borghese, B., & Santulli, P. (2019) · Nature Reviews Endocrinology · doi:10.1038/s41574-019-0245-z · Cited by 1,084
Consensus on current management of endometriosis
Johnson, N. P., Hummelshoj, L., for the World Endometriosis Society Montpellier Consortium, Abrao, M. S., Adamson, G. D., Allaire, C., Amelung, V., Andersson, E., Becker, C., Birna Árdal, K. B., et al. (2013) · Human Reproduction · doi:10.1093/humrep/det050 · Cited by 558
Self-citationSystematic review of endometriosis pain assessment: how to choose a scale?
Bourdel, N., Alves, J., Pickering, G., Ramilo, I., Roman, H., & Canis, M. (2015) · Human Reproduction Update · doi:10.1093/humupd/dmu046 · Cited by 372
Reevaluating response and failure of medical treatment of endometriosis: a systematic review
Becker, C. M., Gattrell, W. T., Gude, K., & Singh, S. S. (2017) · Fertility and Sterility · doi:10.1016/j.fertnstert.2017.05.004 · Cited by 302
Metadata
- Authors
- Petraglia, F., Hornung, D., Seitz, C., Faustmann, T., Gerlinger, C., Luisi, S., Lazzeri, L., & Strowitzki, T.
- Affiliations
- University of Siena (IT)
- University of Lübeck (DE)
- Bayer (Germany) (DE)
- Heidelberg University (DE)
- Corresponding author
- Petraglia, Felice
- ORCID
- Venue
- Archives of Gynecology and Obstetrics
- Published
- 2011-06-17
- Volume
- 285
- Issue
- 1
- Pages
- 167-173
- ISSN
- 0003-9128 (ISSN-L)
- 0932-0067
- 1432-0711
- PMC
- PMC3249203
- OpenAlex
- W2159474777
- Cited by
- 200
- References
- 23
- Citations by year
- 2026: 9 · 2025: 10 · 2024: 11 · 2023: 7 · 2022: 12 · 2021: 18 · 2020: 8 · 2019: 6 · 2018: 18 · 2017: 25 · 2016: 14 · 2015: 21 · 2014: 18 · 2013: 10 · 2012: 8
- FWCI
- 14.70
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- Locations
- Archives of Gynecology and Obstetrics (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
- Florence Research (University of Florence) (submittedVersion)
- Use Siena air (University of Siena) (submittedVersion)
- Funders
- Bayer HealthCare
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Endometriosis Research and Treatment
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Menstrual Health and Disorders
- Health Sciences › Medicine › Obstetrics and Gynecology › Gynecological conditions and treatments
- Keywords
- endometriosis, dienogest, long-term treatment, pelvic pain, dysmenorrhea, bleeding patterns, treatment discontinuation, open-label extension, adverse events, treatment efficacy and safety
- MeSH terms
- Adolescent, Adult, Drug Administration Schedule, Endometriosis, Female, Follow-Up Studies, Germany, Hormone Antagonists, Humans, Italy, Middle Aged, Nandrolone, Ukraine, Pelvic Pain, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Reduced pelvic pain in women with endometriosis: efficacy of long-term dienogest treatment. https://app.cochat.ai/papers/10.1007/s00404-011-1941-7
- The paper
- Petraglia, F., Hornung, D., Seitz, C., Faustmann, T., Gerlinger, C., Luisi, S., Lazzeri, L., & Strowitzki, T. (2012). Reduced pelvic pain in women with endometriosis: efficacy of long-term dienogest treatment. Archives of Gynecology and Obstetrics. https://doi.org/10.1007/s00404-011-1941-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.